Search Results - "DeFor, T E"

Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I–II clinical trial by MacMillan, M L, Blazar, B R, DeFor, T E, Wagner, J E

“…Suboptimal neutrophil and platelet recovery after unrelated donor umbilical cord blood transplantation (UCBT) may be due in part to an impaired…”
Get full text

Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival by Rogosheske, J R, Fargen, A D, DeFor, T E, Warlick, E, Arora, M, Blazar, B R, Weisdorf, D J, Brunstein, C G

“…We studied whether early CsA trough levels were associated with the risk of acute GVHD in 337 patients after either sibling PBSC or double umbilical cord blood…”
Get full text

New classification of chronic GVHD: added clarity from the consensus diagnoses by Arora, M, Nagaraj, S, Witte, J, DeFor, T E, MacMillan, M, Burns, L J, Weisdorf, D J

“…The Diagnosis and Staging Working Group of the NIH Consensus Development Project on Criteria for Clinical Trials in chronic GVHD (CGVHD) recently proposed…”
Get full text

Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units by Brunstein, C G, Barker, J N, Weisdorf, D J, DeFor, T E, McKenna, D, Chong, S Y, Miller, J S, McGlave, P B, Wagner, J E

“…The time to neutrophil engraftment for adult patients after myeloablative double unit umbilical cord blood (UCB) transplantation is 23 days when the two units…”
Get full text

Factors predicting single-unit predominance after double umbilical cord blood transplantation by Ramirez, P, Wagner, J E, DeFor, T E, Blazar, B R, Verneris, M R, Miller, J S, McKenna, D H, Weisdorf, D J, McGlave, P B, Brunstein, C G

“…Double umbilical cord blood transplantation (dUCBT), developed as a strategy to treat large number of patients with hematologic malignancies, frequently leads…”
Get full text

The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML by Hagen, P, Wagner, J E, DeFor, T E, Dolan, M, Arora, M, Warlick, E, Weisdorf, D, Brunstein, C G

“…Whether or not the benefits of antithymocyte globulin (ATG) on engraftment and GVHD are offset by increased risk of relapse, delayed T-cell recovery and…”
Get full text

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I II trial by BURNS, L. J, WEISDORF, D. J, MILLER, J. S, DEFOR, T. E, VESOLE, D. H, REPKA, T. L, BLAZAR, B. R, BURGER, S. R, PANOSKALTSIS-MORTARI, A, KEEVER-TAYLOR, C. A, ZHANG, M-J

“…We determined the safety, immune activating effects, and potential efficacy of i.v. infusion of ex vivo interleukin-2 (IL-2) activated natural killer (NK)…”
Get full text

Characterization and management of hypercalcemia following transplantation for osteopetrosis by Martinez, C, Polgreen, L E, DeFor, T E, Kivisto, T, Petryk, A, Tolar, J, Orchard, P J

“…Autosomal recessive osteopetrosis (OP) is characterized by insufficient osteoclast activity resulting in defective bone resorption and marked increase in…”
Get full text

Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome by Trottier, B J, Sachs, Z, DeFor, T E, Shune, L, Dolan, M, Weisdorf, D J, Ustun, C, Warlick, E D

“…Among patients with myelodysplastic syndrome (MDS) undergoing hematopoietic cell transplantation (HCT), the impact of residual pretransplant cytogenetically…”
Get full text

A modified comorbidity index for hematopoietic cell transplantation by DeFor, T E, Majhail, N S, Weisdorf, D J, Brunstein, C G, McAvoy, S, Arora, M, Le, C T

“…A recent validation analysis at our center among allogeneic hematopoietic cell transplant (HCT) recipients did not find the HCT-specific comorbidity index…”
Get full text

Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors by FRASER, C. J, WEIGEL, B. J, PERENTESIS, J. P, DUSENBERY, K. E, DEFOR, T. E, BAKER, K. S, VERNERIS, M. R

“…The prognosis for many pediatric and young adult patients with solid tumors that have metastasized at the time of diagnosis or have relapsed after therapy…”
Get full text

Bone marrow transplant with post‐transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts by Ebens, C.L., McGrath, J.A., Tamai, K., Hovnanian, A., Wagner, J.E., Riddle, M.J., Keene, D.R., DeFor, T.E., Tryon, R., Chen, M., Woodley, D.T., Hook, K., Tolar, J.

“…Summary Background Recessive dystrophic epidermolysis bullosa (RDEB) is a severe systemic genodermatosis lacking therapies beyond supportive care for its…”
Get full text

CD56 dim CD57 + NKG2C + NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT by Cichocki, F, Cooley, S, Davis, Z, DeFor, TE, Schlums, H, Zhang, B, Brunstein, CG, Blazar, BR, Wagner, J, Diamond, DJ

Get full text

Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning by MAJHAIL, N. S, PARKS, K, DEFOR, T. E, WEISDORF, D. J

“…Allogeneic hematopoietic cell transplantation (HCT) using reduced-intensity conditioning (RIC) has lower morbidity and mortality compared to transplantation…”
Get full text

Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial by MacMillan, M. L., Auerbach, A. D., Davies, S. M., DeFor, T. E., Gillio, A., Giller, R., Harris, R., Cairo, M., Dusenbery, K., Hirsch, B., Ramsay, N. K. C., Weisdorf, D. J., Wagner, J. E.

“…Allogeneic haematopoietic cell transplantation (HCT) is the only therapeutic modality capable of correcting the haematologic manifestations of Fanconi anaemia…”
Get full text

Outcome of second hematopoietic cell transplantation in Hurler syndrome by GREWAL, S. S, KRIVIT, W, DEFOR, T. E, SHAPIRO, E. G, ORCHARD, P. J, ABEL, S. L, LOCKMAN, L. A, ZIEGLER, R. S, DUSENBERY, K. E, PETERS, C

“…Hurler syndrome (HS) is an autosomal recessive, inherited metabolic storage disorder due to deficiency of lysosomal alpha-L-iduronidase (IDU) enzyme activity…”
Get full text

Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning by Phelan, R, Mann, E, Napurski, C, DeFor, T E, Petryk, A, Miller, W P, Wagner, J E, Verneris, M R, Smith, A R

“…Gonadal failure is a health and quality-of-life concern in hematopoietic cell transplant (HCT) survivors. While ovarian dysfunction is nearly universal…”
Get full text

Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation by BURNS, L. J, MILLER, W, KANDASWAMY, C, DEFOR, T. E, MACMILLAN, M. L, VAN BURIK, J.-A, WEISDORF, D. J

“…Cytomegalovirus (CMV) disease remains a major cause of morbidity following allogeneic stem cell transplantation (SCT). In a prospective randomized trial, we…”
Get full text

Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML by Ustun, C, Wiseman, A C, DeFor, T E, Yohe, S, Linden, M A, Oran, B, Burke, M, Warlick, E, Miller, J S, Weisdorf, D

“…Reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (allo-HCT) can cure patients with AML in CR. However, relapse after RIC…”
Get full text

Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402 by Turcotte, L M, DeFor, T E, Newell, L F, Cutler, C S, Verneris, M R, Wu, J, Howard, A, MacMillan, M L, Antin, J H, Vercellotti, G M, Slungaard, Ane, Blazar, B R, Weisdorf, D J, Panoskaltsis-Mortari, A, Holtan, S G

“…Follistatin is an angiogenic factor elevated in the circulation after allogeneic hematopoietic cell transplantation (HCT). Elevations in follistatin plasma…”
Get full text